Unpacking the True Costs of TQQQ: Beyond the $82 Fee
Money

Unpacking the True Costs of TQQQ: Beyond the $82 Fee

authorBy Bola Sokunbi
DateJul 05, 2026
Read Time3 min

Investing in leveraged exchange-traded funds (ETFs) like ProShares UltraPro QQQ (TQQQ) can appear appealing due to the promise of amplified returns. However, the apparent $82 annual fee for a $10,000 investment is merely the tip of the iceberg when considering the actual financial implications. This article explores the significant, yet frequently undisclosed, costs associated with TQQQ, particularly focusing on the phenomenon known as volatility decay, which can substantially diminish an investor's potential gains over time. Understanding these underlying mechanisms is crucial for anyone considering TQQQ for their portfolio, especially for long-term holding strategies.

Many investors are drawn to TQQQ with the expectation of achieving triple the returns of the Nasdaq-100 index. Yet, historical data reveals a stark difference between expectation and reality. Over a recent five-year period, while the Invesco QQQ Trust (QQQ), a proxy for the Nasdaq-100, yielded a return of approximately 107%, TQQQ delivered only about 177.7%. This outcome is significantly lower than the anticipated 323% return that a pure 3x leverage would suggest. The substantial gap of roughly 145 percentage points represents a hidden cost not readily apparent in the fund's promotional materials.

The primary driver behind this discrepancy is TQQQ's daily rebalancing strategy. Unlike traditional ETFs that maintain a consistent exposure, TQQQ rebalances its leverage every single day to achieve its 3x target. This means that after a market decline, the fund is compelled to sell assets to reduce its leveraged position, effectively selling low. Conversely, following an upward market swing, it buys more assets to maintain leverage, thereby buying high. This continuous adjustment in fluctuating markets leads to what experts term "volatility decay," which erodes performance over anything but very short holding periods. Financial analysts frequently caution that this characteristic makes TQQQ an unsuitable investment for those with a long-term horizon.

Even though the fund's expense ratio of 0.82% (or $82 per $10,000 invested annually) is clearly stated, it is dwarfed by the impact of volatility decay. To put this in perspective, comparable unleveraged funds like QQQ and QQQM have expense ratios of 0.20% and 0.15%, respectively. While the fee difference alone can amount to over $1,200 over two decades for a $10,000 investment when compared to QQQM, the losses incurred from volatility decay can be far more substantial. For instance, during a moderately volatile 12-month period, TQQQ returned 96.44% against QQQ's 33.49% — nearly three times, but still shy of a perfect triple. However, over a five-year span that included significant market turbulence, TQQQ only captured about 1.65 times QQQ's return, highlighting the profound impact of decay. Major financial institutions, including Goldman Sachs, Citibank, and Cantor Fitzgerald, categorize TQQQ as a specialized instrument for experienced investors engaged in short-term tactical trading, explicitly stating it is not designed for long-term ownership.

For investors seeking direct exposure to the Nasdaq-100 without the complexities and hidden costs of leveraged products, QQQ and QQQM offer viable alternatives. These funds hold the same basket of 100 stocks, but without leverage, daily rebalancing, or the performance erosion caused by volatility decay. While they won't deliver triple the returns in a booming year, they also protect investors from the severe downturns experienced in volatile periods. The choice hinges on a clear trade-off: sacrificing the potential for extreme leveraged gains for a more stable, compounding investment strategy. Therefore, it is imperative for investors to evaluate whether the promised amplified returns of TQQQ genuinely compensate for its inherent fees and the significant risk of volatility decay, coupled with the potential for substantial losses during market corrections.

More Articles
Money
H.C. Wainwright Upgrades Prime Medicine (PRME) to "Buy" Following Key Clinical Advancements
H.C. Wainwright has revised its rating for Prime Medicine (PRME) from "Neutral" to "Buy," setting an $8 price target. This upgrade reflects significant progress in Prime Medicine's gene-editing pipeline, including the acceptance of a clinical trial application for PM577a in New Zealand for Wilson's disease and the FDA's Regenerative Medicine Advanced Therapy designation for PM359, a stem cell therapy for chronic granulomatous disease. These milestones position PRME as a promising investment in the biotechnology sector.
By Chika UwazieJul 05, 2026
Money
Forager Capital Management's Acquisition Proposal for Repay Holdings
Forager Capital Management has submitted an unsolicited, non-binding proposal to acquire all outstanding shares of Repay Holdings Corporation for $5.25 per share in cash. Repay's Board of Directors is currently evaluating this offer with the assistance of legal and financial advisors, advising shareholders to take no immediate action. Repay Holdings is a payment technology company specializing in integrated electronic payment solutions.
By T. Harv EkerJul 05, 2026
Money
Netskope's Market Outlook: KeyBanc's "Overweight" Rating and a $15 Price Target Explained
KeyBanc has reiterated an "Overweight" rating on Netskope (NTSK) with a $15 price target, despite lowering it from $15. This decision follows a survey highlighting increased AI spending, positioning Netskope as a strong player in the security, data, and infrastructure sectors. TD Cowen also maintains a "Buy" rating with a $19 target, citing robust industry trends and expected free cash flow growth. The stock's current valuation is considered compelling, even with a year-to-date decline of over 30%.
By Vicki RobinJul 05, 2026
Money
Cantor Fitzgerald Sets Ambitious $700 Price Target for AMD, Citing Dominance in AI Chip Race
Cantor Fitzgerald analyst C.J. Muse has significantly raised his price target for Advanced Micro Devices (AMD) to $700, positioning it as the top pick in the computing sector, ahead of Nvidia and Broadcom. This bold prediction comes as AMD demonstrates strong momentum in the AI chip market, despite recent stock fluctuations and broader market skepticism regarding its valuation. The analyst's confidence is rooted in AMD's robust data center growth and the increasing demand for its high-performance chips, particularly its EPYC Venice server processors and AI accelerators.
By Scott PapeJul 05, 2026
Money
Hedge Fund Divests Significant Stake in Establishment Labs Amidst Strong Performance
JW Asset Management, a hedge fund, recently sold 90,533 shares of Establishment Labs Holdings Inc. for approximately $6.64 million. Despite this substantial divestment, the fund retains a significant holding, indicating continued bullish sentiment. This transaction occurred as Establishment Labs experienced robust revenue growth and inclusion in the Russell 2000 Index, driving its stock to a 52-week high.
By Ramit SethiJul 05, 2026